Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$712M |
| 2 |
PepsiCo
PEP
|
+$669M |
| 3 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$635M |
| 4 |
Walmart Inc
WMT
|
+$544M |
| 5 |
Palantir
PLTR
|
+$538M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.34B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.65B |
| 3 |
Tesla
TSLA
|
+$1.45B |
| 4 |
Invesco QQQ Trust
QQQ
|
+$1.01B |
| 5 |
Apple
AAPL
|
+$833M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.48% |
| 2 | Financials | 7.27% |
| 3 | Consumer Discretionary | 6.82% |
| 4 | Communication Services | 5.06% |
| 5 | Healthcare | 4.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2901
Replimune Group
REPL
$941M
| $1.91M | ﹤0.01% |
455,862
+83,752
| +23% | +$535K |
|
2902
Byline Bancorp
BY
$1.78B
| $1.91M | ﹤0.01% |
68,720
-5,599
| -8% | -$156K |
|
2903
Healthcare Services Group
HCSG
$1.6B
| $1.9M | ﹤0.01% |
113,145
-116,042
| -51% | -$1.73M |
|
2904
Teradata
TDC
$2.92B
| $1.9M | ﹤0.01% |
88,505
-6,676
| -7% | -$144K |
|
|
BBUC
2905
Brookfield Business Corp Class A Subordinate Voting Shares
BBUC
$6.12B
| $1.9M | ﹤0.01% |
56,746
-890
| -2% | -$28.8K |
|
2906
RLJ Lodging Trust
RLJ
$1.86B
| $1.9M | ﹤0.01% |
264,247
-80,886
| -23% | -$610K |
|
2907
Sibanye-Stillwater
SBSW
$6.26B
| $1.9M | ﹤0.01% |
169,208
-147,657
| -47% | -$1.29M |
|
2908
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
$18.5B
| $1.9M | ﹤0.01% |
35,110
+5,360
| +18% | +$287K |
|
2909
Virtus Investment Partners
VRTS
$1.06B
| $1.9M | ﹤0.01% |
9,988
-5,594
| -36% | -$1.1M |
|
2910
Aurinia Pharmaceuticals
AUPH
$1.91B
| $1.9M | ﹤0.01% |
171,600
-78,720
| -31% | -$860K |
|
2911
CALL
Xerox
XRX
$387M
| $1.88M | ﹤0.01% |
500,000
| – | – |
|
2912
Weis Markets
WMK
$1.91B
| $1.88M | ﹤0.01% |
26,145
-5,352
| -17% | -$391K |
|
2913
Sana Biotechnology
SANA
$871M
| $1.87M | ﹤0.01% |
525,856
+31,441
| +6% | +$114K |
|
2914
iShares MSCI USA Momentum Factor ETF
MTUM
$25B
| $1.86M | ﹤0.01% |
7,248
+6,531
| +911% | +$1.6M |
|
2915
CALL
Amphenol
APH
$198B
| $1.86M | ﹤0.01% |
+15,000
| New | +$1.65M |
|
2916
PUT
Lumentum
LITE
$55.5B
| $1.85M | ﹤0.01% |
+11,400
| New | +$1.42M |
|
|
AIV
2917
Aimco
AIV
$387M
| $1.85M | ﹤0.01% |
232,958
-249,905
| -52% | -$2.03M |
|
2918
QCR Holdings
QCRH
$1.69B
| $1.85M | ﹤0.01% |
24,419
-12,160
| -33% | -$916K |
|
2919
Blue Owl Capital
OBDC
$5.34B
| $1.84M | ﹤0.01% |
144,358
-477,496
| -77% | -$6.8M |
|
2920
LegalZoom.com
LZ
$1.35B
| $1.84M | ﹤0.01% |
177,342
-60,892
| -26% | -$607K |
|
|
JAMF
2921
DELISTED
Jamf
JAMF
| $1.84M | ﹤0.01% |
171,690
+7,401
| +5% | +$67K |
|
2922
Nuvation Bio
NUVB
$2.2B
| $1.83M | ﹤0.01% |
495,934
-523,631
| -51% | -$1.43M |
|
|
ORKA
2923
Oruka Therapeutics
ORKA
$5.82B
| $1.83M | ﹤0.01% |
95,330
+4,166
| +5% | +$61.8K |
|
2924
CALL
Conagra Brands
CAG
$6.94B
| $1.83M | ﹤0.01% |
100,000
| – | – |
|
|
2925
PUT
Conagra Brands
CAG
$6.94B
| $1.83M | ﹤0.01% |
100,000
| – | – |
|
Similar funds
Barclays's Q3 2025 Portfolio in Review
As of Q3 2025, Barclays held 5,800 positions worth $461B, up 5.7% from $436B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Barclays's Q3 2025 filing shows 615 new, 1,596 increased, 2,751 reduced and 340 closed positions. Its largest new stake was Paramount Skydance Corp: 13,646,704 shares worth $258M. The largest sale was NVIDIA, an estimated $2.34B.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
- Barclays's largest Q3 2025 buy was Paramount Skydance Corp: 13,646,704 shares worth $258M.
- Barclays added most to iShares iBoxx $ High Yield Corporate Bond ETF in Q3 2025, an estimated $712M increase.
- Barclays's biggest Q3 2025 reduction was NVIDIA, cutting an estimated $2.34B.
- Barclays fully exited Blueprint Medicines in Q3 2025, selling an estimated $200M.
- Barclays's ten largest holdings make up 40% of its $461B portfolio in Q3 2025.
- Barclays opened 615 new positions and closed 340 in Q3 2025.
- Barclays's portfolio value rose 5.7% quarter-over-quarter to $461B.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.